<DOC>
	<DOCNO>NCT00066430</DOCNO>
	<brief_summary>RATIONALE : Infrared coagulation may effective preventing development anal cancer patient anal neoplasia . PURPOSE : Pilot study evaluate effectiveness infrared coagulation prevent anal cancer HIV-positive patient high-grade anal neoplasia .</brief_summary>
	<brief_title>Infrared Coagulation Preventing Anal Cancer Patients With HIV Who Have Anal Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine recurrence rate high-grade squamous intraepithelial neoplasia anal canal HIV-positive patient treat infrared coagulation . - Determine time recurrence time progression patient treated procedure . - Determine toxicity procedure patient . - Correlate CD4/CD8 count HIV viral load outcome patient treated procedure . - Correlate outcome human papilloma virus subtype patient treated procedure . OUTLINE : This open-label , pilot , multicenter study . Patients undergo treatment infrared coagulator direct contact lesion 1.5 second necrotic tissue debrided . Treatment repeat level submucosal vessel colposcopic guidance . A repeat biopsy perform 3 month assess treatment success . Patients incompletely treated lesion receive 1 treatment . Up 3 lesion treat visit absence disease progression unacceptable toxicity . Patients complete questionnaire regard anal pain discomfort baseline , 4 week , 3 , 6 , 9 , 12 month . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 18 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIV positive Presence internal anal lesion histologically confirm highgrade squamous intraepithelial neoplasia least 1 positive margin No 3 lesion , 10 mm diameter No evidence microscopic invasion anal biopsy specimens No history anal cancer PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Platelet count least 50,000/mm^3 CD4 count least 50 cells/mm^3 Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy lidocaine No anal insertion , include enemas anal intercourse , 24 hour least 1 week study treatment No prior severe photosensitivity reaction No active opportunistic infection No concurrent neoplasia require cytotoxic therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Must stable regimen highly active antiretroviral therapy ( HAART ) least 12 week prior study entry unless CD4 count &gt; 200/mm^3 AND plan initiate HAART within next 3 month More 14 day since prior acute treatment infection medical illness No prior infrared coagulation anal dysplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>anal cancer</keyword>
	<keyword>high-grade squamous intraepithelial lesion</keyword>
</DOC>